| Market Closed - Nasdaq Other stock markets | 5-day change | 1st Jan Change | ||
| 43.12 USD | -3.41% |  | +3.23% | -9.83% |
| Jun. 12 | Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025 | MT |
| Jun. 12 | Ultragenyx Pharmaceutical Launches Equity Offering | MT |
Presenter SpeechSalveen Richter (Analysts)Good morning. Thank you so much for joining us. Real...
This article is reserved for subscribers
Signed up already?
Log In
Not subscribed yet?
Subscribe
Latest news about Ultragenyx Pharmaceutical Inc.
| Ultragenyx Plans to File Biologics License Application for UX111 Late This Year or Early 2025 | MT | |
| Ultragenyx Pharmaceutical Launches Equity Offering | MT | |
| Ultragenyx Pharmaceuticals to Seek Accelerated Approval of Genetic Disease Treatment | DJ | |
| Ultragenyx Pharmaceutical Inc. Announces Successful Meeting with the FDA | CI | |
| Sector Update: Health Care Stocks Ease Late Afternoon | MT | |
| Sector Update: Health Care | MT | |
| Ultragenyx, Mereo BioPharma Shares Rise as Bone Disorder Drug Shows Reduced Fracture Rate | MT | |
| Sector Update: Health Care Stocks Rise Premarket Wednesday | MT | |
| Sector Update: Health Care | MT | |
| Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc Announce Positive 14-Month Results from the Phase 2 Portion of the Ongoing Phase 2/3 Orbit Study | CI | |
| Ultragenyx, Mereo BioPharma Say Phase 2 Study of Bone Disorder Drug Showed Reduced Fracture Rate | MT | |
| Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM | ||
| Goldman Sachs Upgrades Ultragenyx Pharmaceutical to Buy From Neutral, Raises Price Target to $67 From $56 | MT | |
| Cantor Fitzgerald Adjusts Price Target on Ultragenyx Pharmaceutical to $115 From $107, Maintains Overweight Rating | MT | |
| Stifel Adjusts Price Target on Ultragenyx Pharmaceutical to $127 From $124, Maintains Buy Rating | MT | |
| Baird Raises Price Target on Ultragenyx Pharmaceutical to $72 From $68, Maintains Outperform Rating | MT | |
| Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $48 From $47, Keeps Neutral Rating | MT | |
| Transcript : Ultragenyx Pharmaceutical Inc. - Special Call | ||
| Ultragenyx Pharmaceutical Inc. Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia | CI | |
| Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT | |
| Transcript : Ultragenyx Pharmaceutical Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 01:40 PM | ||
| Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT | |
| Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 | ||
| Earnings Flash (RARE) ULTRAGENYX PHARMACEUTICAL Posts Q1 Revenue $108.8M | MT | |
| Ultragenyx Pharmaceutical Inc. Reaffirms Earnings Guidance for the Year 2024 | CI |
Chart Ultragenyx Pharmaceutical Inc.
More charts
Company Profile
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. The Companyâs four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of hom*ozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, and UX701. DTX401 for the treatment of glycogen storage disease type la.
Sector
Calendar
2024-06-18 - Annual General Meeting
More about the company
Income Statement Evolution
More financial data
Ratings for Ultragenyx Pharmaceutical Inc.
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
43.12USD
Average target price
90.95USD
Spread / Average Target
+110.92%
Consensus
EPS Revisions
Estimates Revisions
Quarterly earnings - Rate of surprise
Company calendar
Sector Bio Therapeutic Drugs
| 1st Jan change | Capi. | |
|---|---|---|
ULTRAGENYX PHARMACEUTICAL INC. | -9.83% | 3.58B |
VERTEX PHARMACEUTICALS INCORPORATED | +17.73% | 124B |
REGENERON PHARMACEUTICALS, INC. | +16.88% | 111B |
BIONTECH SE | -9.04% | 23.17B |
ARGENX SE | +4.40% | 22.94B |
WUXI APPTEC CO., LTD. | -38.15% | 17.42B |
BEIGENE, LTD. | -7.75% | 17.42B |
GENMAB A/S | -15.36% | 16.9B |
NEUROCRINE BIOSCIENCES, INC. | +3.42% | 13.71B |
SAREPTA THERAPEUTICS, INC. | +29.63% | 11.82B |
Bio Therapeutic Drugs
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Transcript : Ultragenyx Pharmaceutical Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10
